ZIOPHARM Oncology's [ZIOP] CEO, Dr. Jonathan Lewis, to Ring The NASDAQ Stock Market Opening Bell
Published on Monday, 18 June 2012 10:08 Written by TradersHuddle Staff
ADVISORY, June 18, 2012 (GLOBE NEWSWIRE) --
ZIOPHARM Oncology Inc. [ZIOP], a biopharmaceutical company focused on the development and commercialization of new cancer therapies, will visit the NASDAQ MarketSite in Times Square.
In honor of the occasion, Dr. Jonathan Lewis, CEO, will ring the Opening Bell.
NASDAQ MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
Tuesday, June 19, 2012 – 9:15 a.m. to 9:30 a.m. ET
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
Facebook and Twitter:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.
For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx
A live webcast of the NASDAQ Opening Bell will be available at: http://www.nasdaq.com/about/marketsitetowervideo.asx.
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About ZIOPHARM Oncology Inc [ZIOP]:
ZIOPHARM Oncology is a biopharmaceutical company focused on the development and commercialization of new cancer therapies. The Company's clinical programs include:
Palifosfamide (ZIO-201), a novel DNA-targeted cancer treatment that bypasses drug resistance mediated by ALDH (aldehyde dehydrogenase), an enzyme associated with cancer stem cells, and has a favorable toxicity profile. Intravenous palifosfamide is currently being studied in a randomized, double-blinded, placebo-controlled Phase 3 trial (PICASSO 3) for the treatment of front-line metastatic soft tissue sarcoma and is also in a pivotal Phase 3 trial (MATISSE) for front-line metastatic small cell lung cancer. Additionally, the Company is developing an oral capsule form of palifosfamide.
IL-12 DNA, a novel DNA therapeutic that is delivered to the patient's tumor and expresses interleukin-12, a protein that controls anti-cancer immune responses. IL-12 DNA is currently in two Phase 1 studies, with plans to move into Phase 2 studies. ZIOPHARM's DNA therapeutics are being developed in partnership with Intrexon Corporation through a revolutionary synthetic biology platform that allows for targeted, controlled production of therapies in humans with a biologic on/off switch (the RheoSwitch Therapeutic System®). Preclinical and discovery work with multiple therapeutic approaches, such as antibodies, immunotoxins, and protein decoys, is expected to result in multiple clinical candidates in the next 12 to 24 months.
Indibulin (ZIO-301) is a novel, tubulin binding agent that is expected to have several potential benefits, including oral dosing, application in multi-drug resistant tumors, no neuropathy and a tolerable toxicity profile. It is currently being studied in a Phase 1/2 trial in metastatic breast cancer.
Darinaparsin (ZIO-101) is a novel mitochondrial- and hedgehog-targeted agent (organic arsenic) currently in ongoing studies with Solasia Pharma K.K.
ZIOPHARM's operations are located in Boston, MA; Germantown, MD; and New York City. Further information about ZIOPHARM may be found at www.ziopharm.com.
About NASDAQ OMX:
The inventor of the electronic exchange, The NASDAQ OMX Group, Inc., fuels economies and provides transformative technologies for the entire lifecycle of a trade - from risk management to trade to surveillance to clearing. In the US and Europe, we own and operate 24 markets, 3 clearinghouses and 5 central securities depositories supporting equities, options, fixed income, derivatives, commodities, futures and structured products. Able to process more than 1 million messages per second at sub-40 microsecond speeds with 99.999% uptime, our technology drives more than 70 marketplaces in 50 developed and emerging countries into the future, powering 1 in 10 of the world's securities transactions. Our award-winning data products and worldwide indexes are the benchmarks in the financial industry. Home to approximately 3,400 listed companies worth $5.1 trillion in market cap whose innovations shape our world, we give the ideas of tomorrow access to capital today. Welcome to where the world takes a big leap forward, daily. Welcome to the NASDAQ OMX Century. To learn more, visit www.nasdaqomx.com. Follow us on Facebook (http://www.facebook.com/NASDAQ) and Twitter (http://www.twitter.com/nasdaqomx). (Symbol: NDAQ and member of S&P 500).
- Bulls taking Control of NASDAQ?
- Neutral Short Term Pattern on NASDAQ
- NASDAQ: Waiting for Direction
- Is NASDAQ Trade Over?
- NASDAQ Short term Bullish Reversal
- NASDAQ Bearish Signs
- Brazil's Market Surveillance Project Goes Live Across All Markets at BM&FBOVESPA
- National Geographic Channel's Brain Games to Ring The NASDAQ Stock Market Closing Bell
- NASDAQ OMX Corporate Solutions Selected to Provide the Scottish Public Sector With a Collaborative Media Services Framework
- New York Cares to Ring The NASDAQ Stock Market Opening Bell
Related Partner Headlines
- Sandy Forces Closure of Stock Markets Through Tuesday - TheStreet.com
- UPDATE: NASDAQ Stock Market to be Closed on Tuesday - Benzinga
- Stock Markets Closed as Superstorm Looms - TheStreet.com
- Top 4 Mid-Cap Stocks In The Diversified Investments Industry With The Highest Cash - Benzinga
- The NASDAQ Stock Market to be Closed on Monday October 29 - Benzinga
- ZIOPHARM Provides Update on Phase 1 Study of Ad-RTS IL-12 in Advanced Melanoma - Benzinga
- Ziopharm: Options Trade for Phase III Data - TheStreet.com
- ZIOPHARMA Responds to Negative Blog Post; Say Statements are Misleading and Wrong - Benzinga
- Top 4 Mid-Cap Stocks In The Diversified Investments Industry With The Highest EPS Estimates - Benzinga
- NASDAQ OMX Group Inc. (NDAQ): Today's Featured Financial Services Laggard - TheStreet.com
Latest Partner Headlines
Dow Today: Verizon Communications (VZ) Higher - TheStreet.com
Separating the Bargains From the Busts - TheStreet.com
Cramer Quick Take: The 60-Inch TV Will Be Key This Holiday - TheStreet.com
Cramer Quick Take: Cisco Wins If Fiscal Cliff Is Resolved - TheStreet.com
Gap Up and Sit - TheStreet.com
Apple, Intel, MicroStrategy: Tech Winners & Losers - TheStreet.com
Windows 8 PC Sales Disappointing: Report - TheStreet.com
Cramer Quick Take: Buy Home Depot and Lowe's - TheStreet.com
Dow JonesCompany ID [INDEXDJX:.DJI] Last trade:15,307.17 Trade time:4:44PM EDT Value change:▼80.41 (-0.52%)
S&P 500Company ID [INDEXSP:.INX] Last trade:1,655.35 Trade time:4:43PM EDT Value change:▼13.81 (-0.83%)
NASDAQCompany ID [INDEXNASDAQ:.IXIC] Last trade:3,463.30 Trade time:5:15PM EDT Value change:▼38.82 (-1.11%)
In The Wires
Bellatrix Exploration Ltd. Announces The Annual Board of Director Election Results
Kingsway Announces Acquisition of HVAC Warranty Business
Heska Corporation to Present at the Stifel Dental & Veterinary Conference
Blackstone Mortgage Trust, Inc. Announces Upsizing And Pricing Of Public Offering Of Class A Common Stock
CME Group Inc. Announces Preliminary Results from its 2013 Annual Meeting of Shareholders
SNC-Lavalin retains investment grade rating
The Laclede Group Prices Public Offering of Common Stock
AccelerateOTT: Revving Up Ottawa’s Startup Engine; a Community Led Event Hosted by Invest Ottawa and the C100